Cyclandelate

Summary

Cyclandelate (CHEMBL1480987) is an approved small-molecule vasodilator agent (ATC C04AX01); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C04AX01
• Indications: 1 condition
• Chemistry: 276.4 Da · C17H24O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1480987
Name	Cyclandelate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2893
ChEBI	CHEBI:3988
ATC	C04AX01
Molecular formula	C17H24O3
Molecular weight	276.4
InChIKey	WZHCOOQXZCIUNC-UHFFFAOYSA-N

SMILES: CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O

IUPAC name: (3,3,5-trimethylcyclohexyl) 2-hydroxy-2-phenylacetate

ChEBI definition: The ester obtained by formal condensation of mandelic acid and 3,3,5-tricyclohexanol. It is a direct-acting smooth muscle relaxant used to dilate blood vessels.

Pharmacological roles (ChEBI): vasodilator agent.

Also known as: Ciclandelato, Cyclandelate, Cyclergine, Cyclobral, Cyclolyt, Cyclomandol, Cyclospasmol, Natil, Novodil, NSC-758910, Perebral, Spasmocyclon (3m)

Patent coverage: 1,459 distinct patent families (4,523 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, Ferritin light chain, Nuclear receptor subfamily 1 group I member 2, Bile salt export pump.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR1I2	5.28	AC50	5300	nM	CHEMBL_ACT_25188533

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).